Darapladib

Drug Profile

Darapladib

Alternative Names: 480848; SB-480848

Latest Information Update: 26 Dec 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline; Human Genome Sciences
  • Developer GlaxoSmithKline
  • Class Acetamides; Fluorobenzenes; Pyrimidinones; Small molecules; Sulfides
  • Mechanism of Action 1-alkyl-2-acetylglycerophosphocholine esterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Atherosclerosis; Diabetic macular oedema

Most Recent Events

  • 12 Nov 2016 Adverse events data from the phase III SOLID-TIMI 52 trial in Atherosclerosis presented at the 89th Annual Scientific Sessions of the American Heart Association
  • 01 Aug 2014 GlaxoSmithKline completes a phase I pharmacodynamic trial in Atherosclerosis (in patients with Type-2 diabetes mellitus) in United Kingdom (NCT02058641)
  • 30 Jun 2014 Discontinued - Phase-III for Atherosclerosis in South Korea, Japan, Norway, India, Hong Kong, Ukraine, Russia, Thailand, New Zealand, Taiwan, Pakistan, Philippines, Turkey, Israel, Colombia, Peru, Chile, Brazil, Mexico, Germany, France, Denmark, Czech Republic, Bulgaria, Belgium, Canada, Romania, Poland, the Netherlands, Italy, Hungary, South Africa, Sweden, Spain, Slovakia, Australia, Estonia, Greece, United Kingdom, China, Argentina and USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top